GET DAILY SIGNALSArcturus Therapeutics (ARCT) Delivers Q3 Beat as Pipeline Momentum Builds
Key Takeaways
- Third quarter 2026 revenue rose to $18.3 million, up from $17.2 million in the prior-year period, lifted by a $12.0 million termination payment from CSL Seqirus.
- Net loss narrowed to $7.4 million, or $0.26 per share, compared with a loss of $13.4 million, or $0.49 per share, a year earlier.
- Cash and cash equivalents stood at $184.8 million as of September 30, 2026, which management says supports a runway through year-end 2028.
- Results topped consensus estimates, with revenue and per-share results both coming in ahead of analyst expectations.
- Pipeline updates included encouraging Phase 2 data for the ARCT-810 program in ornithine transcarbamylase (OTC) deficiency and the debut of the LUNAR 2.0 delivery platform.
Placing the Quarter in Context
Arcturus Therapeutics (NASDAQ: ARCT) focuses on messenger RNA medicines for liver and respiratory conditions. The third-quarter 2026 update comes at a transitional moment after the company ended its collaboration with CSL Seqirus and regained rights to the KOSTAIVE self-amplifying mRNA COVID vaccine and related programs. Because the firm is still clinical-stage and unprofitable, investors tend to focus more on pipeline progress, cash management, and milestone timing than on near-term earnings. Revenue can swing sharply from one quarter to the next due to collaboration and grant accounting, so the latest numbers help clarify both the financial effects of the transition and whether cost discipline is preserving the cash runway.
What the Numbers Showed
For the quarter ended September 30, 2026, total revenue reached $18.3 million, compared with $17.2 million a year earlier. The gain stemmed mainly from recognition of the $12.0 million termination payment and remaining deferred revenue from the CSL Seqirus arrangement, partly offset by lower grant revenue. The figure comfortably exceeded the consensus estimate of roughly $8.0 million.
Net loss improved to $7.4 million, or $0.26 per share, versus a net loss of $13.4 million, or $0.49 per share, in the same quarter of 2025. On an adjusted basis, the per-share loss also beat the consensus range of roughly $0.60 to $0.68. Research and development expenses fell to $17.0 million from $23.3 million, while general and administrative expenses remained essentially flat at $10.5 million. Cash and cash equivalents totaled $184.8 million at quarter-end, down from $230.9 million at the end of 2025, reflecting continued spending on the cystic fibrosis and OTC deficiency programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How Investors Reacted
Before the release, attention centered on the decline in collaboration revenue alongside steady pipeline advancement. Shares had already risen about 77 percent year-to-date through early November, indicating that optimism around clinical progress was already priced in. The quarter reinforced that view: revenue exceeded expectations, the loss narrowed, and management highlighted positive Phase 2 biomarker data for ARCT-810 along with plans to begin Phase 2 dosing of the next-generation ARCT-2601 candidate. The combination of a top-line beat and clinical updates generally supports sentiment, though ongoing dependence on milestone and collaboration payments remains an important factor to watch.
What Comes Next
Looking ahead, near-term catalysts center on the pipeline rather than the income statement. In cystic fibrosis, enrollment in the Phase 2 ARCT-032 study is expected to finish by the end of 2026, with full Cohort 4 data slated for presentation in the second quarter of 2027. A decision on moving the program into Phase 3 will follow top-line results and could unlock meaningful contributions from partner Thermo Fisher Scientific.
In the liver franchise, Phase 2 dosing of ARCT-2601—the first candidate to use the LUNAR 2.0 delivery platform—is scheduled to start in the first quarter of 2027, with top-line data anticipated in the second half of 2027. Early work continues in phenylketonuria and gout. On the financial side, cash burn and any new business-development activity, especially around the KOSTAIVE vaccine ahead of potential European and U.K. commercialization in 2027, will be worth monitoring. The recent acquisition of MyNeo adds AI-driven mRNA optimization capabilities. Management has indicated the balance sheet supports operations through 2028, so disciplined capital use and successful clinical execution will remain central to the investment thesis. From what I see, continued execution on these milestones will be key.
Exploring Tools for Biotech Research
In my own workflow I occasionally turn to Tickeron’s AI Screener when scanning the biotech sector for comparable names or technical setups. It lets users filter by fundamentals, volatility, and AI signals in a structured way that can surface ideas more quickly than manual review. The platform has been helpful for quickly comparing companies like ARCT against peers on metrics that matter for clinical-stage names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARCT's Stochastic Oscillator remains in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 74 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 40 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.798) is normal, around the industry mean (2.904). P/E Ratio (-3.264) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology and therapeutics for rare diseases
Industry Biotechnology
Advertisement